Compare DexCom, Inc. (DXCM) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Intuitive Surgical, Inc. — how do they compare? DexCom, Inc. trades at $83.63 (market cap $31.86B), while Intuitive Surgical, Inc. trades at $426.69 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 4.6× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Intuitive Surgical, Inc. for 84 Days on average.
| DXCM | ISRG | |
|---|---|---|
Market Cap | $31.86B | $146.76B |
Volume | 3,607,070 | 2,529,814 |
Sector | Health | Health |
52-Week High | $92.34 | $592.85 |
52-Week Low | $54.84 | $332.02 |
Typical Hold Time | 62 Days | 84 Days |
Enterprise Value | $31.32B | $141.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
